title: Novel treatments for NEC: keeping IBD in mind.
abstract: Necrotizing enterocolitis (NEC) is an inflammatory intestinal disease of premature newborns, thought to result in part from overactivity of the innate immune system. NEC has been well-studied from the perspective of prevention; however, after the disease onset, there are limited treatment options to control its progression. This review discusses four potential therapies that target the overactive immune response in NEC: pentoxifylline, platelet activating factor modulators, glucocorticoids, and vasoactive substances. In addition, given the similar pathogenesis of NEC and inflammatory bowel disease (IBD), we propose that IBD therapies could provide promising leads for novel strategies with which to treat NEC.
authors.affiliation: Section of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, USA. harpavat@bcm.edu
authors.forename: Sanjiv
authors.initials: S
authors.lastname: Harpavat
authors.forename: Mohan
authors.initials: M
authors.lastname: Pammi
authors.forename: Mark
authors.initials: M
authors.lastname: Gilger
mesh_terms: D020345:Enterocolitis, Necrotizing / Q000188:drug therapy* / Q000503:physiopathology; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000503:physiopathology; D007413:Intestinal Mucosa / Q000473:pathology; D010431:Pentoxifylline / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010972:Platelet Activating Factor / Q000627:therapeutic use*
chemical_list: D005938:Glucocorticoids; D010726:Phosphodiesterase Inhibitors; D010972:Platelet Activating Factor; D010431:Pentoxifylline